[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":182,"collaborators":11,"id":184,"slug":185,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":11,"eligibilityCriteria":190,"healthyVolunteers":186,"sex":191,"minAge":192,"maxAge":11,"enrollmentInfo":193,"targetDuration":11,"studyType":196,"phases":197,"briefSummary":199,"conditions":200,"keywords":208,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EXS73565","EXPERIMENTAL",null,[13],"Drug: EXS73565",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","EXS73565 oral administration",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[26,39,50,59,68,79,90,99,108,117,128,134,139,144,153,164,174],{"facility":27,"status":28,"city":29,"state":11,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"LLC ARENSIA Exploratory Medicine","RECRUITING","Tbilisi","119","Georgia","GE",{"type":34,"coordinates":35},"Point",[36,37],44.83412,41.69143,{"lat":37,"lon":36},{"facility":40,"status":28,"city":41,"state":11,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":11},"Laiko General Hospital of Athens","Athens","115 26","Greece","GR",{"type":34,"coordinates":46},[47,48],23.72784,37.98376,{"lat":48,"lon":47},{"facility":51,"status":28,"city":52,"state":11,"zip":53,"country":43,"countryCode":44,"cosmosGeoPoint":54,"geoPoint":58,"contacts":11},"University General Hospital of Patras","Pátrai","2650",{"type":34,"coordinates":55},[56,57],21.73508,38.2462,{"lat":57,"lon":56},{"facility":60,"status":28,"city":61,"state":11,"zip":62,"country":43,"countryCode":44,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"General Hosptial of Thessaloniko G. Papanikolaou","Thessaloniki","570 10",{"type":34,"coordinates":64},[65,66],22.93493,40.64072,{"lat":66,"lon":65},{"facility":69,"status":28,"city":70,"state":11,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"IMSP Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","MD-2025","Moldova","MD",{"type":34,"coordinates":75},[76,77],28.85938,47.00902,{"lat":77,"lon":76},{"facility":80,"status":28,"city":81,"state":11,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":11},"Pratia MCM","Krakow","30-727","Poland","PL",{"type":34,"coordinates":86},[87,88],19.93658,50.06143,{"lat":88,"lon":87},{"facility":91,"status":28,"city":92,"state":11,"zip":93,"country":83,"countryCode":84,"cosmosGeoPoint":94,"geoPoint":98,"contacts":11},"Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologi (Copernicus Memorial Hospital)","Lodz","95-513",{"type":34,"coordinates":95},[96,97],19.47395,51.77058,{"lat":97,"lon":96},{"facility":100,"status":28,"city":101,"state":11,"zip":102,"country":83,"countryCode":84,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie","Lublin","20-090",{"type":34,"coordinates":104},[105,106],22.57009,51.25058,{"lat":106,"lon":105},{"facility":109,"status":28,"city":110,"state":11,"zip":111,"country":83,"countryCode":84,"cosmosGeoPoint":112,"geoPoint":116,"contacts":11},"Aidport Sp. z o.o. - PPDS","Skórzewo","60-185",{"type":34,"coordinates":113},[114,115],17.81889,53.03629,{"lat":115,"lon":114},{"facility":118,"status":28,"city":119,"state":11,"zip":120,"country":121,"countryCode":122,"cosmosGeoPoint":123,"geoPoint":127,"contacts":11},"Hospital Beata Maria Ana","Madrid","28007","Spain","ES",{"type":34,"coordinates":124},[125,126],-3.70256,40.4165,{"lat":126,"lon":125},{"facility":129,"status":28,"city":119,"state":11,"zip":130,"country":121,"countryCode":122,"cosmosGeoPoint":131,"geoPoint":133,"contacts":11},"MD Anderson Cancer Center Madrid","28033",{"type":34,"coordinates":132},[125,126],{"lat":126,"lon":125},{"facility":135,"status":28,"city":119,"state":11,"zip":11,"country":121,"countryCode":122,"cosmosGeoPoint":136,"geoPoint":138,"contacts":11},"Hospital Fundación Jiménez Diaz",{"type":34,"coordinates":137},[125,126],{"lat":126,"lon":125},{"facility":140,"status":28,"city":119,"state":11,"zip":11,"country":121,"countryCode":122,"cosmosGeoPoint":141,"geoPoint":143,"contacts":11},"Hospital Universitario HM Sanchinarro",{"type":34,"coordinates":142},[125,126],{"lat":126,"lon":125},{"facility":145,"status":28,"city":146,"state":11,"zip":147,"country":121,"countryCode":122,"cosmosGeoPoint":148,"geoPoint":152,"contacts":11},"Clinica Universidad de Navarra","Pamplona","31008",{"type":34,"coordinates":149},[150,151],-1.64323,42.81687,{"lat":151,"lon":150},{"facility":154,"status":28,"city":155,"state":11,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv","01135","Ukraine","UA",{"type":34,"coordinates":160},[161,162],30.5238,50.45466,{"lat":162,"lon":161},{"facility":165,"status":28,"city":166,"state":11,"zip":11,"country":167,"countryCode":168,"cosmosGeoPoint":169,"geoPoint":173,"contacts":11},"St James's University Hospital","Leeds","United Kingdom","UK",{"type":34,"coordinates":170},[171,172],-1.54785,53.79648,{"lat":172,"lon":171},{"facility":175,"status":28,"city":176,"state":11,"zip":11,"country":167,"countryCode":168,"cosmosGeoPoint":177,"geoPoint":181,"contacts":11},"University Hospitals Plymouth NHS Trust (Derriford Hospital)","Plymouth",{"type":34,"coordinates":178},[179,180],-4.14305,50.37153,{"lat":180,"lon":179},{"type":183,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414",false,"NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.","ALL","18 Years",{"count":194,"type":195},85,"ESTIMATED","INTERVENTIONAL",[198],"PHASE1","The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[201,202,203,204,205,206,207],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[209,210,203,204,205,206,207,211],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-08-11",{"date":214,"type":215},"2026-08-13","ACTUAL",{"date":217,"type":215},"2025-03-31",{"date":219,"type":195},"2028-12",{"name":221,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",17]